Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 extension study of rVIII-SingleChain in severe hemophilia A
NL-OMON47544Phase 3Active, not recruiting
- Sponsor
- CSL Limited
- Start
- Nov 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of lonoctocog alfa in hemophilia A (4 arms), sponsored by CSL Limited. Primary endpoints: Incidence rate of inhibitor formation in previously treated patients, Incidence of high-titer inhibitor formation in previously untreated patients and 2 more. Started Nov 2014; status: active, not recruiting.
02
Drugs
lonoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON47544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47544.